464 related articles for article (PubMed ID: 29632282)
21. Apheresis treatment in Lambert-Eaton myasthenic syndrome.
Motomura M; Hamasaki S; Nakane S; Fukuda T; Nakao YK
Ther Apher; 2000 Aug; 4(4):287-90. PubMed ID: 10975475
[TBL] [Abstract][Full Text] [Related]
22. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.
Pellkofer HL; Armbruster L; Krumbholz M; Titulaer MJ; Verschuuren JJ; Schumm F; Voltz R
J Neuroimmunol; 2008 Nov; 204(1-2):136-9. PubMed ID: 18809213
[TBL] [Abstract][Full Text] [Related]
23. Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy.
Takamori M; Maruta T; Komai K
Neurosci Res; 2000 Mar; 36(3):183-91. PubMed ID: 10683522
[TBL] [Abstract][Full Text] [Related]
24. [Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions].
Honnorat J
Bull Acad Natl Med; 2014 Feb; 198(2):243-54; discussion 255. PubMed ID: 26263702
[TBL] [Abstract][Full Text] [Related]
25. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
Titulaer MJ; Lang B; Verschuuren JJ
Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
[TBL] [Abstract][Full Text] [Related]
26. Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism.
Gable KL; Massey JM
Semin Neurol; 2015 Aug; 35(4):340-6. PubMed ID: 26502758
[TBL] [Abstract][Full Text] [Related]
27. Lambert-Eaton myasthenic syndrome.
Mareska M; Gutmann L
Semin Neurol; 2004 Jun; 24(2):149-53. PubMed ID: 15257511
[TBL] [Abstract][Full Text] [Related]
28. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.
Lang B; Pinto A; Giovannini F; Newsom-Davis J; Vincent A
Ann N Y Acad Sci; 2003 Sep; 998():187-95. PubMed ID: 14592874
[TBL] [Abstract][Full Text] [Related]
29. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.
Titulaer MJ; Klooster R; Potman M; Sabater L; Graus F; Hegeman IM; Thijssen PE; Wirtz PW; Twijnstra A; Smitt PA; van der Maarel SM; Verschuuren JJ
J Clin Oncol; 2009 Sep; 27(26):4260-7. PubMed ID: 19667272
[TBL] [Abstract][Full Text] [Related]
30. Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome Associated with Neuroendocrine Carcinoma of the Oropharynx.
Takasugi J; Shimamura M; Koda T; Kishikawa T; Hanamoto A; Inohara H; Sato K; Morii E; Motomura M; Sakaguchi M; Nakatsuji Y; Mochizuki H
Intern Med; 2018 Feb; 57(4):587-590. PubMed ID: 29093415
[TBL] [Abstract][Full Text] [Related]
31. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
Sabater L; Titulaer M; Saiz A; Verschuuren J; Güre AO; Graus F
Neurology; 2008 Mar; 70(12):924-8. PubMed ID: 18032743
[TBL] [Abstract][Full Text] [Related]
32. [Seronegative nonparaneoplastic Lambert-Eaton myasthenic syndrome].
Sanadze AG; Sidnev DV; Tumurov DA
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(5):77-80. PubMed ID: 28638036
[TBL] [Abstract][Full Text] [Related]
33. Lambert-Eaton Myasthenic Syndrome.
Kesner VG; Oh SJ; Dimachkie MM; Barohn RJ
Neurol Clin; 2018 May; 36(2):379-394. PubMed ID: 29655456
[TBL] [Abstract][Full Text] [Related]
34. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.
Flink MT; Atchison WD
J Bioenerg Biomembr; 2003 Dec; 35(6):697-718. PubMed ID: 15000529
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer.
Liu Y; Xi J; Zhou L; Wu H; Yue D; Zhu W; Lin J; Lu J; Zhao C; Qiao K
J Clin Neurosci; 2019 Jul; 65():41-45. PubMed ID: 31072737
[TBL] [Abstract][Full Text] [Related]
36. Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission.
Flink MT; Atchison WD
J Physiol; 2002 Sep; 543(Pt 2):567-76. PubMed ID: 12205190
[TBL] [Abstract][Full Text] [Related]
37. [The pathophysiology and treatment of autoimmune neuromuscular junction diseases].
Motomura M
Rinsho Shinkeigaku; 2011 Nov; 51(11):872-6. PubMed ID: 22277398
[TBL] [Abstract][Full Text] [Related]
38. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system.
Voltz R; Carpentier AF; Rosenfeld MR; Posner JB; Dalmau J
Muscle Nerve; 1999 Jan; 22(1):119-22. PubMed ID: 9883867
[TBL] [Abstract][Full Text] [Related]
39. [LEMS: Clinical Significance of Pathogenic Autoantibodies].
Motomura M; Irioka T
Brain Nerve; 2023 Jul; 75(7):837-845. PubMed ID: 37431074
[TBL] [Abstract][Full Text] [Related]
40. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder.
Vincent A; Lang B; Newsom-Davis J
Trends Neurosci; 1989 Dec; 12(12):496-502. PubMed ID: 2480664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
